Hepatocellular Carcinoma Clinical Trial
Official title:
TACE Combined With Sorafenib and PD-1 mAb in the Treatment of BCLC B/C Hepatocellular Carcinoma: Single Arm, Single Center, Open Label Study
Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death that
ranks sixth in terms of incident cases, with an overall 5 years survival of 18%. Despite a
significant improvement in treatment strategy, the overall survival of HCC remains low due to
high recurrence, progressive liver dysfunction and the high fatality of the disease. Surgical
resection has been applied in a number of patients; however, surgery has been associated with
a high incidence of recurrence (approximately 70% within 5 years). TACE is generally applied
on intermediate-stage HCC. However, TACE is not satisfied with improving overall survival.
Therefore, there is an urgent need for effective treatment for these patients.
At present, the overall objective response rate (ORR) of single or sequential therapy is not
satisfied, and the over survival (OS) improvement is not ideal. Therefore, combined therapy
maybe the good choice for patients with advanced HCC.
This study focuses on the in-operable, BCLC-B/C HCC patients. Through the combination of
local therapy (TACE), anti-angiogenic therapy (Sorafenib), and immunotherapy (PD-1 monoclonal
antibody), it is expected to change the tumor microenvironment, restore the immune response,
strengthen the anti-tumor effect of various treatments, and improve the therapeutic efficacy
in patients with BCLC-B/C HCC.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | January 31, 2023 |
Est. primary completion date | July 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Histopathologically or clinically confirmed hepatocellular carcinoma. 2. Age = 18 years old. 3. Performance status (PS) = 2 (ECOG scale). 4. Barcelona clinical liver cancer (BCLC) stage B or stage C. 5. Participants who have not received other systemic anti-tumor treatment for HCC before the first administration. 6. Patients who had not received TACE before the first administration, or who had received 0-2 times TACE but PD or SD = 4 weeks. 7. According to mRECIST, there is at least one measurable lesion. 8. Child Pugh score = 7. 9. Participant has sufficient organ and marrow functions. 10. Expected survival time = 12 weeks. 11. For women of childbearing age or male patients whose sexual partners are women of childbearing age, effective contraceptive measures should be taken during the whole treatment period and 6 months after the last medication. 12. Sign the written informed consent, and be able to follow the visit and relevant procedures specified in the plan Exclusion Criteria: 1. Fibrolamellar carcinoma, sarcomatoid carcinoma, cholangiocarcinoma and other components previously confirmed by histology / cytology. 2. History of hepatic encephalopathy or liver transplantation. 3. Pleural effusion, ascites and pericardial effusion with clinical symptoms requiring drainage. 4. Tumor burden=70%, diffuse liver cancer or tumor is not suitable for mRECIST standard evaluation. 5. Received local treatment (ablation therapy), surgery resection and radiotherapy for liver cancer before the first administration. 6. Have received systemic chemotherapy, targeted therapy or immunotherapy 7. There is a significant decrease in white blood cells and platelets in peripheral blood, severe coagulation dysfunction and can not be corrected:the neutrophil<1.5×109/L, PLT<50×109/L. The INR>2.3 8. Acute or chronic active hepatitis B or C infection, hepatitis B virus (HBV-DNA) > 10^6 copies / ml; hepatitis C virus (HCV-RNA) > 10^3 copies / ml; HBsAg and anti HCV antibody were positive at the same time. 9. There is central nervous system metastasis. 10. Bleeding of esophageal or gastric varices caused by portal hypertension occurred in the past 6 months, or severe (G3) varices were found in endoscopic examination within 3 months before the first administration, or evidence of portal hypertension (including splenomegaly found in imaging examination) was found. The researchers assessed that the risk of bleeding was high and did not receive sclerotherapy or ligation under the endoscope. 11. The previous 6-month history of arteriovenous thromboembolism, including myocardial infarction, unstable angina, cerebrovascular accident, pulmonary embolism, deep vein thrombosis or any other serious thromboembolism. The thrombus of implanted vein port or catheter source or superficial vein is stable after routine anticoagulant treatment. Prophylactic use of low- molecular-weight heparin (e.g., enoxaparin 40 mg / day) is permitted. 12. Tumor thrombus of main portal vein, or involving superior mesenteric vein at the same time. 13. Aspirin (> 325 mg / day) or other drugs known to inhibit platelet function such as dipyridamole or clopidogrel were used for 7 consecutive days within 2 weeks before the first administration. 14. For uncontrolled hypertension, systolic blood pressure > 150 mmHg or diastolic blood pressure > 100 mmHg after the best medical treatment, hypertension crisis or hypertension encephalopathy history. 15. Symptomatic congestive heart failure (New York Heart Association class II-IV). Symptomatic or poorly controlled arrhythmias. The corrected QT interval (QTc) for the history or screening of congenital long QT syndrome was more than 500 ms (calculated by Fridericia method). 16. Serious bleeding tendency or coagulation dysfunction, or undergoing thrombolysis. 17. In the past 6 months, there was a history of gastrointestinal perforation and / or fistula, a history of intestinal obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), extensive enterotomy (partial colectomy or extensive enterotomy with chronic diarrhea), Crohn's disease, ulcerative colitis or long-term chronic diarrhea. 18. Previous and current pulmonary fibrosis history, interstitial pneumonia, pneumoconiosis, drug-related pneumonia, severe impairment of lung function and other lung diseases. 19. Active tuberculosis (TB), who is receiving anti TB treatment or has received anti TB treatment within one year before the first administration. 20. People with HIV infection (HIV 1 / 2 antibody positive) and known syphilis infection. Serious infection in active stage or poor clinical control. 21. Severe infection within 4 weeks before the first administration, including but not limited to hospitalization due to complications of infection, bacteremia or severe pneumonia. 22. Active autoimmune diseases requiring systemic treatment (such as the use of disease alleviation drugs, corticosteroids or immunosuppressants) occurred within 2 years before the first administration. Alternative therapies (e.g. thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) are permitted. Known history of primary immunodeficiency. Only the patients with positive autoimmune antibody need to confirm whether there is autoimmune disease according to the judgment of researchers. 23. Immunosuppressive drugs were used within 4 weeks before the first administration, excluding local glucocorticoids or systemic glucocorticoids (i.e. no more than 10 Mg / day prednisone or the equivalent dose of other glucocorticoids), allowing temporary use of glucocorticoids due to dyspnea symptoms in the treatment of asthma, chronic obstructive pulmonary disease and other diseases. 24. Receive live attenuated vaccine within 4 weeks before the first administration or during the study period. 25. Major surgical procedures (craniotomy, thoracotomy or open hand) were performed within 4 weeks before the first administration (surgery) or an unhealed wound, ulcer, or fracture. 26. Uncontrolled / uncorrectable metabolic disorder or other non- malignant organ disease or systemic disease or cancer secondary reaction, which may lead to higher medical risk and / or uncertainty of survival evaluation. 27. Known to be allergic to any PD-1 monoclonal antibody component. 28. Women of childbearing age who are unwilling or unable to use acceptable methods of contraception during the whole treatment period of this trial and within 12 weeks after the last administration of the study drug (women of childbearing age include: any women who have had menarche, and have not undergone successful artificial sterilization (hysterectomy, bilateral tubal ligation, or bilateral ovariectomy), pregnancy or lactation Women; women with positive pregnancy test results at the time of inclusion or before study drug administration; If the partner is a woman of childbearing age, the subject is a fertile male without effective contraceptive measures. |
Country | Name | City | State |
---|---|---|---|
China | Sichuan Cancer Hospital and Research Institute | Chengdu | Sichuan |
Lead Sponsor | Collaborator |
---|---|
Sichuan Cancer Hospital and Research Institute |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | conversion rate of hepatectomy | The ratio of patients with locally advanced liver cancer who could not be operated on before to get radical operation through comprehensive treatment | 1 year | |
Primary | objective response rate (ORR) | The proportion of patients whose tumor volume reduction reaches the predetermined value and can maintain the minimum time limit. It is the sum of the proportion of complete response (CR) and partial response(PR). That is, ORR = CR + PR | Change from baseline tumor volume at 6 months | |
Primary | overall survival (OS) | the time from the beginning of treatment to death caused by any reason (the last follow-up time is for the patients who lost the visit; the end of the study is for the patients who are still alive) | 1 year | |
Secondary | progression free survival (PFS) | Progression free survival period refers to the period from the beginning of treatment to the time when patients with cancer progress is observed or death occurs for any reason. | Up to 24 months, from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months | |
Secondary | time to progression (TTP) | Time from the beginning of treatment to the objective progression of tumor | Up to 24 months, from date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months | |
Secondary | disease control rate (DCR) | It is the sum of the proportion of complete response (CR), partial response(PR) and stable disease(SD). That is, DCR = CR + PR + SD | 1 year | |
Secondary | duration of response | the time from the first evaluation of the tumor as CR or PR to the first evaluation as PD or any cause of death | up to 48 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04209491 -
Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
|
||
Completed |
NCT03963206 -
Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
|
Phase 4 | |
Completed |
NCT03268499 -
TACE Emulsion Versus Suspension
|
Phase 2 | |
Recruiting |
NCT05263830 -
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
|
||
Recruiting |
NCT05044676 -
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
|
||
Recruiting |
NCT05095519 -
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
|
Phase 2 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Completed |
NCT05068193 -
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Active, not recruiting |
NCT04039607 -
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
|
Phase 3 | |
Terminated |
NCT03970616 -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT03642561 -
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
|
Phase 2/Phase 3 | |
Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 |